JPMorgan Chase tops profit expectations as bank benefits from higher rates, benign credit

JPMorgan Chase tops profit expectations as bank benefits from higher rates, benign credit


Jamie Dimon, chairman and CEO of JPMorgan Chase, at the U.S. Capitol for a lunch meeting with the New Democrat Coalition in Washington, D.C., June 6, 2023.

Nathan Howard | Bloomberg | Getty Images

JPMorgan Chase topped analysts’ expectations for third-quarter profit and revenue as the bank generated more interest income than expected, while credit costs came in lower than expected.

Here’s what the company reported:

  • Earnings per share: $4.33
  • Revenue: $40.69 billion, vs. $39.63 billion LSEG estimate

Reported earnings per share of $4.33 were not immediately comparable to the LSEG estimate of $3.96.

JPMorgan will be watched closely for clues on how the industry fared amid surging interest rates and rising loan losses.

While the biggest U.S. bank by assets has navigated volatile rates adeptly so far this year, the situation has caught several peers off guard, including a trio of midsized lenders that collapsed after deposit runs.

Bank stocks plunged last month after the Federal Reserve signaled it would keep interest rates higher for longer than expected to fight inflation amid unexpectedly robust economic growth. The 10-year Treasury yield, a key figure for long-term rates, jumped 74 basis points in the third quarter. One basis point equals one-hundredth of a percentage point.

Higher rates hit banks in several ways. The industry has been forced to pay up for deposits as customers shift holdings into higher-yielding instruments like money market funds. Rising yields mean the bonds owned by banks fall in value, creating unrealized losses that pressure capital levels. And higher borrowing costs tamp down demand for mortgages and corporate loans.

Banks including JPMorgan have also been setting aside more funds for anticipated loan losses.

Wall Street may provide little help this quarter, with investment banking fees likely to remain subdued and trading revenue expected to be flat or down slightly.

Finally, analysts will want to hear what CEO Jamie Dimon has to say about the economy and his expectations for the banking industry. Dimon has been vocal in his opposition against proposed increases in capital requirements.

Shares of JPMorgan have climbed 8.7% year to date, far outperforming the 19% decline of the KBW Bank Index.

Wells Fargo and Citigroup are scheduled to release results later Friday morning. Bank of America and Goldman Sachs report Tuesday, and Morgan Stanley discloses results on Wednesday.

This story is developing. Please check back for updates.



Source

E.l.f. Beauty posts earnings beat, raises full-year guidance
Business

E.l.f. Beauty posts earnings beat, raises full-year guidance

Elf Beauty cosmetics Courtesy: e.l.f Beauty E.l.f. Beauty reported a huge earnings beat Wednesday and raised its guidance for the fiscal year. E.l.f. stock was up as much as 15% in after-hours trading before losing the majority of those gains. Here’s what the company reported for the third fiscal quarter, compared with analyst estimates from […]

Read More
Terrell Owens calls Hall of Fame process ‘broken’ after Belichick, Kraft snubs
Business

Terrell Owens calls Hall of Fame process ‘broken’ after Belichick, Kraft snubs

NFL Hall of Famer Terrell Owens said Wednesday that the recent snubs of New England Patriots owner Robert Kraft and former coach Bill Belichick from the institution show the system is flawed, and someone needs to be held accountable. “It’s just plain dumb” Owens told CNBC Sport in an interview in San Francisco ahead of […]

Read More
Eli Lilly’s GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
Business

Eli Lilly’s GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026

The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters It’s a tale of two drugmakers in the red-hot obesity drug market.  Both Novo Nordisk and Eli Lilly are grappling with lower prices in the U.S., but their 2026 outlooks are diverging sharply: While Novo is bracing for a sales decline, […]

Read More